US 11,655,260 B2
Heterocyclic compounds as arginase inhibitors
Zhaoyin Wang, Guangzhou (CN); Nanxin Li, Guangzhou (CN); Jianbin Ma, Guangzhou (CN); and Yanqiang Shao, Guangzhou (CN)
Assigned to GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD., Guangzhou (CN)
Appl. No. 16/956,693
Filed by Guangdong Newopp Biopharmaceuticals Co., Ltd., Guangzhou (CN)
PCT Filed Dec. 21, 2018, PCT No. PCT/CN2018/122815
§ 371(c)(1), (2) Date Jun. 22, 2020,
PCT Pub. No. WO2019/120296, PCT Pub. Date Jun. 27, 2019.
Claims priority of provisional application 62/708,773, filed on Dec. 22, 2017.
Prior Publication US 2020/0325161 A1, Oct. 15, 2020
Int. Cl. C07F 5/02 (2006.01); A61K 45/06 (2006.01)
CPC C07F 5/025 (2013.01) [A61K 45/06 (2013.01)] 6 Claims
 
1. A compound represented by Formula (I), or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt, stereoisomer, tautomer, or prodrug thereof,
wherein
R1 is selected from H, straight or branched (C1-6)alkyl, (C3-6)cycloalkyl, (C3-10) cycloalkyl-(C1-6)alkylene-, (C5-10)aryl-(C1-12)alkylene-, (C1-10)heteroaryl-(C1-12)alkylene-, (C3-10)heterocycloalkyl-(C1-12)alkylene- and (C1-6)alkyl-C(O)-;
R2 is selected from ORa, and NRbRc;
Ra, Rb, Rc is selected from hydrogen, straight or branched (C1-12) alkyl, (C3-12) cycloalkyl, (C3-10)cycloalkyl-(C1-12)alkylene-, (C5-10)aryl-(C1-12)alkylene-, (C1-)heteroaryl-(C1-12)alkylene-, (C3-10)heterocycloalkyl-(C1-12)alkylene-, Ra, Rb, Rc is optionally substituted with R5;
R3 and R4 are independently selected from hydrogen, straight or branched (C1-6)alkyl, (C3-8)cycloalkyl, (C3-8)cycloalkyl(C1-6)alkylene, substituted (C3-8)cycloalkyl(C1-6)alkylene, (C5-12)aryl; R3 and R4 can be connected with one or two bonds, when it is connected by two bonds, it form another ring other than the ring containing B and O;
Y, Y1 and Y2 forming a ring structure having 1 to 10 carbon atoms, wherein each of Y, Y1 and Y2 is independently selected from substituted or unsubstituted alkylene, alkenylene, alkynylene, arylene, and cycloalkylene, wherein one or more —CH2— groups in Y are optionally and independently replaced with a moiety Q that is selected from O, NRi, S, S(O), S(O)2, and CR5R6; or wherein any two adjacent —CH2— groups optionally are replaced by a cycloalkylene group, provided that Y does not contain two adjacent Q moieties selected from O, NRi, S, S(O), and S(O)2;
R5 and R6 are independently chosen from halogen, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C3-12 cycloalkyl, C6-12 aryl, C3-12 heterocyclyl, C1-12 heteroaryl, —S(O)mR7, —S(O)2NRjRk, —S(O)2OR7, —NO2, —NRjRk, —(CR8R9)nOR7, —CN, —C(O)R7, —OC(O)R7, —O(CR8R9)nR7, —NR7C(O)R10, —(CR8R9)nC(O)OR7, —(CR8R9)nC(O)NRjRk, —(CR8R9)nNRjRk, —C(═NRj)NRjRk, —NR7C(O)NRjRk, —NR7S(O)2R10 or SF5, Ri, Rj and Rk are defined as the same as for Rb and Rc and each hydrogen in R5 and R6 may be unsubstituted or substituted by R10, and wherein R5 and R6 on adjacent atoms are uncombined or combine to form a C6-12 aryl, 5-12 membered heteroaryl, C3-12 cycloalkyl or 3-12 membered heteroalicyclyl;
m is 0, 1 or 2;
n selected from 0 to 10;
R7, R8 and R9 are independently chosen from hydrogen, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C3-12 cycloalkyl, C6-12 aryl, 3-12 membered heteroalicyclyl, 5-12 membered heteroaryl; R8 and R9 together with the carbon atom to which they are bound form a 3-, 4-, 5- or 6-membered ring that is fully saturated, or partially saturated and that optionally contains 1-3 additional heteroatom ring members selected from 0, S, and NR, wherein the ring is optionally fused with a cycloalkyl, heterocyclic or aromatic ring; R7, R8 and R9 are optionally substituted with R10;
R10 may be chosen from halogen, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C3-12 cycloalkyl, C6-12 aryl, 3-12 membered heterocyclic ring, 5-12 membered heteroaryl ring, —NH2, —CN, —OH, —O—C1-12alkyl, —O—(CH2)nC3-12 cycloalkyl, —O—(CH2),C6-12 aryl, —O—(CH2)n(3-12 membered heterocyclyl) or —O—(CH2)n(5-12 membered heteroaryl); and each hydrogen in R10 may be unsubstituted or substituted by R11;
R11 may be chosen from halogen, C1-12 alkyl, C1-12 alkoxy, C3-12 cycloalkyl, C6-12 aryl, 3-12 membered heterocyclyl, 5-12 membered heteroaryl, —O—C1-12 alkyl, —O—(CH2)nC3-12 cycloalkyl, —O—(CH2),C6-12 aryl, —O—(CH2)n(3-12 membered heterocyclyl), —O—(CH2)n(5-12 membered heteroaryl) or —CN, and each hydrogen in R11 may be unsubstituted or substituted by halogen, —OH, —CN, —C1-12 alkyl which may be unsubstituted, or partially halogenated or fully halogenated, —O—C1-12 alkyl which may be unsubstituted or partially halogenated or fully halogenated, or substituted with —C(O) Ra;
V is selected from —S(O)2NRjRk, —S(O)2OR7 or

OG Complex Work Unit Chemistry
R7, Ri, Rj and Rk are defined as the same as for Rb and Rc and each hydrogen in R7 may be unsubstituted or substituted by R10.